ArticleFrontiers in endocrinology2025
Antidiabetic and lipid-lowering therapy modify the association between triglyceride-glucose index and acute kidney injury in critically ill patients with coronary artery disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triglyceride-Glucose Index and Acute Kidney Injury: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a common and serious complication in critically ill coronary artery disease (CAD) patients. The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, has been linked to adverse cardiovascular and renal outcomes. However, whether antidiabetic drugs or lipid-lowering drugs modify its association with AKI in this population remains unclear. Methods: This study retrospectively analyzed 2,517 critically ill CAD patients from the MIMIC-IV database. Patients were stratified according to the use of antidiabetic and lipid-lowering drugs. The primary endpoint was the occurrence of AKI during hospitalization. Multivariable logistic regression and restricted cubic spline (RCS) models were applied to examine the association between the TyG index and AKI risk. Subgroup analyses, sensitivity analyses, and independent external validation were performed to assess the robustness of the findings. Results: The median age of patients was 69 years, and 68.06% were male. In the fully adjusted logistic regression model, a higher TyG index was significantly associated with an increased risk of AKI among patients without the use of antidiabetic drugs (OR 2.021, 95% CI 1.674-2.454) or lipid-lowering drugs (OR 1.912, 95% CI 1.648-2.228). With the use of antidiabetic drugs, this association remained significant but was attenuated (OR 1.480, 95% CI 1.190-1.853), with a significant interaction observed between the use of antidiabetic drugs and the TyG index in relation to AKI risk (P for interaction = 0.040). With the use of lipid-lowering drugs, the association between the TyG index and AKI risk was weakened (OR 1.445, 95% CI 0.934-2.307), but no significant interaction was found (P for interaction = 0.332). RCS analyses demonstrated a linear relationship between higher TyG index values and increased AKI risk. Similar results were confirmed in external validation. Conclusions: In critically ill CAD patients, a higher TyG index was independently associated with an increased risk of AKI, whereas this association was attenuated in those with the use of antidiabetic or lipid-lowering drugs. These findings highlight the importance of incorporating metabolic risk assessment into the management of critically ill patients and underscore the potential of pharmacological interventions to improve renal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.